## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Hu et al. 10/041,770 Application No.: Group Art Unit: 1645 January 8, 2002 Filed: Novel Human Protease and Polynucleotides Examiner: Not Yet Assigned Encoding the Same ttorney Docket No.: LEX-0294-USA Assistant Commissioner for Patents Arlington, VA 22202 Box DD INFORMATION DISCLOSURE STATEMENT Dear Sir: This Information Disclosure Statement is submitted: X under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last) under 37 CFR 1.97(c) together with either a: \_\_ Certification under 37 CFR 1.97(e), or a \$240.00 fee under 37 CFR 1.17(p), or (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) under 37 CFR 1.97(d) together with a: Certification under 37 CFR 1.97(e), and \_\_\_ a petition under 37 CFR 1.97(d)(2)(ii), and \_\_\_ a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee) Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there

may be a duty to disclose in accordance with 37 CFR 1.56.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

PATENT & TRUDOMARK OFFICE

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

April 18, 2002

Date

Rechards 6

Reg. No. 41,866

LEXICON GENETICS INCORPORATED (281) 863-3333

24231

PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	Complete if Known			
TITO DILLETION DISCUSSION OF THE	Application Number	10/041,770		
NE ORMATION DISCLOSURE	Filing Date	January 8, 2002		
STATEMENT BY APPLICANT	First Named Inventor	Hu		
) , (i)	Group Art Unit	1645		
2 3 2002 🕃 use as many sheets as necessary)	Examiner Name	Not Yet Assigned		
Sheet S 1 of 3	Attorney Docket Number	1 EX-0204-118A		

Attorney Docket Number

LEX-0294-USA

Cite	U.S. Patent I	D		<del></del>	
No.1	U.S. Patent Document  Kind Code <sup>2</sup> Number  (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant
ΔΔ	4 215 051	(	Schroeder et al	07/20/90	Figures Appear
	<del>                                     </del>				<u> </u>
AC				<del></del>	
AD	<del></del>	<del></del>		<del></del>	
AE				<del></del>	
AF				<del></del>	
AG					
AH				<del></del>	
Al					
AJ					
				· , , , , , , , , , , , , , , , , , , ,	
AL	5,445,934		Fodor et al	<del></del>	
AM	5,459,127		Felgner et al	10/17/95	
AN :	5,556,752		Lockhart et al	09/17/96	
AO	5,700,637		Southern	12/23/97	
ΑP	5,744,305		Fodor et al	04/28/98	
4Q	5,830,721		Stemmer et al	11/03/98	
AR.	5,837,458		Minshuil et al	11/17/98	
48	5,869,336		Meyer et al.	02/09/99	
ΑT	5,877,397		Lonberg et al	03/02/99	
¥U	5,922,546		Mayer et al	07/13/99	
٩V	5,948,767		Scheule et al.	09/07/99	
λW	6,075,181		Kucherlapati et al	06/13/00	
\X	6,110,490		Thierry	08/29/00	
λY	6,114,598		Kucherlapati et al	09/05/00	
vz	6,150,584		Kucherlapati et al.	11/21/00	
<u> </u>					
	AAA ABB AC AD AE AF AG AH AI AI AI AN	AA 4,215,051  AB 4,376,110  AC 4,594,595  AD 4,631,211  AE 4,689,405  AF 4,713,326  AG 4,873,191  AH 4,946,778  AI 5,252,743  AJ 5,272,057  AK 5,424,186  AL 5,445,934  AM 5,459,127  AN 5,556,752  AO 5,700,637  AP 5,744,305  AQ 5,830,721  AR 5,837,458  AS 5,869,336  AT 5,877,397  AU 5,922,546  AV 5,948,767  AW 6,075,181  AX 6,110,490  AY 6,114,598	(if known)  AA	AAA 4,215,051 Schroeder et al AB 4,376,110 David et al AC 4,594,595 Struckman AD 4,631,211 Houghten AE 4,689,405 Frank et al AG 4,873,191 Wagner et al AH 4,946,778 Ladner et al AH 5,252,743 Barrett et al AU 5,272,057 Smulson et al AU 5,445,934 Fodor et al AU 5,459,127 Felgner et al AU 5,556,752 Lockhart et al AU 5,744,305 Fodor et al AG 5,830,721 Stemmer et al AU 5,837,458 Minshull et al AU 5,922,546 Mayer et al AU 5,948,767 Scheule et al. AU 5,948,767 Scheule et al. AU 5,948,767 Scheule et al. AU 6,075,181 Kucherlapati et al. AU C 6,150,584 Kucherlapati et al.	AAA 4,215,051 Schroeder et al 07/29/80  AB 4,376,110 David et al 03/08/83  AC 4,594,595 Struckman 06/10/86  AB 4,689,405 Frank et al 08/25/87  AF 4,713,326 Dattagupta et al 12/15/87  AG 4,873,191 Wagner et al 08/07/90  AH 4,946,778 Ladner et al 08/07/90  AH 4,946,778 Ladner et al 08/07/90  AU 5,252,743 Barrett et al 10/12/93  AU 5,272,057 Smulson et al 12/21/93  AU 5,272,057 Smulson et al 06/13/95  AU 5,459,127 Felgner et al 09/27/96  AU 5,556,752 Lockhart et al 09/17/96  AU 5,704,305 Fodor et al 09/17/96  AU 5,830,721 Stemmer et al 11/23/98  AU 5,837,458 Minshull et al 11/17/98  AU 5,837,458 Minshull et al 07/13/99  AU 5,922,546 Mayer et al 09/07/99  AU 5,948,767 Scheule et al 09/07/99  AU 5,948,767 Scheule et al 09/05/00  AU 6,075,191 Kucherlapati et al 09/05/00  AU 6,075,191 Kucherlapati et al 09/05/00  AU 6,110,490 Thierry 08/29/00  AU 6,110,584 Kucherlapati et al 09/05/00  AU 6,110,584 Kucherlapati et al 09/05/00  AU 6,110,584 Kucherlapati et al 09/05/00  AU 6,110,584 Kucherlapati et al 11/12/1/00

	· · · · · · · · · · · · · · · · · · ·			
Examiner	,	Date		
	2.10.00	Date	ロコロル	
Signature	1000 -	Considered	1 1/1/91 A	7_
		Oonsidered	101-110	<u> </u>

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
and Trademark Office; U.S. DEPARTMENT OF COMMERCE

. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO					Complete if Known		
INFORMATION DISCLOSURE					Application Number	10/041,770	
					Filing Date	January 8, 2002	
STATEMENT BY APPLICANT				PLICANI	First Named Inventor	Hu	
232	ું	1			Group Art Unit	1645	
2 3 2002 5		(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet		2	of	3	Attorney Docket Number	LEX-0294-USA	

	r	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
xaminer nitials*	Cite No. <sup>1</sup>	and the state of t						
85 T	ВА	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.	T					
7	BB	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.	İ					
	BC	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.	Ī					
	BD	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6625-6641.						
	BE	Gordon, 1989, "Transgenic Animals", International Review of Cytology, 115:171-229.	Ī					
	BF	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.	Ī					
э	BG	Gu et al, 1994, "Deletion of a DNA Polymerase $\beta$ Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", Science 265:103-106.						
	ВН	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.						
	BI	Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single- chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.						
		Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.						
*	BK	Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", Nucleic Acids Research 15(15):6131-6149.						
		Inouye & Inouye, 1985, "Up-promoter mutations in the lpp gene of Escherichia coli", Nucleic Acids Research 13(9):3101-3110.						
		Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS 88:8972-8976.	ĺ					
		Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.						
		Lakso et al, 1992, "Targeted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. Sci. USA 89:6232-6236.	ĺ					
		Lavitrano et al, 1989, "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice", Cell 57:717-723.						
	BQ	Lo, 1983, "Transformation by Iontophoretic Microinjection of DNA: Multiple Integrations without Tandem Insertions", Mol. (Cell. Biology 3(10):1803-1814.						
6		Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.						
	BS	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817-823.	Ī					
		Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.						
		Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.						
	в۷	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.	Ĺ					
	BW .	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of immunology 147:2429-2438.						
4		O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.						



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitu	ite for form 1449B/P	то		Complete if Known		
MEO	RMATION	יז שופכו	OSLIBE	Application Number	10/041,770	
		DA VDD	LOSONE	Filing Date	January 8, 2002	
STATEMENT BY APPLICANT				First Named Inventor	Hu	
2002 5				Group Art Unit	1645	
~ 3	(use as many sh	neets as necessa	ary)	Examiner Name	Not Yet Assigned	
heet	3	of	3	Attorney Docket Number	LEX-0294-USA	

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.  Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.  Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.  Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.  Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research (6(8):3209-3221.  Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.  Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.  Thompson et al, 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting and the standard and the st
Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.  Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.  Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.  Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research (6(8):3209-3221.  Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.  Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.
markers in mouse L cells", Gene 30:147-156.  Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.  Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.  Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research (6(8):3209-3221.  Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.  Fakeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.
methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.  Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.  Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research (6(8):3209-3221.  Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.  Fakeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.
Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.  Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.  Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.  Fakeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.
Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.  Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.
Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.  Fakeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.
onstant region sequences", Nature 314:452-454.
hompson et al, 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targetin
n Embryonic Stem Cells", Cell 56:313-321.
/an Der Putten et al, 1985, "Efficient insertion of genes into the mouse germ line via retroviral vectors", Proc. Natl. Acad. Sci. USA 82:6148-6152.
/an Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 164(10):5503-5509.
Vard et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia oli", Nature 341:544-546.
Vigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232.
Vigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. ISA 77(6):3567-3570.
74 C

Examiner Signature	Date Considered (Z	29/	03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.